- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Rationale:
- Decision makers noted that Aflibercept 8mg is clinically equivalent and of at least equal cost-effectiveness to the NICE recommended aflibercept 2mg formulation (TA 346 and TA294). Therefore, it would not be an efficient use of NHS resources to conduct an evaluation. Aflibercept 8mg should therefore be considered for routine commissioning.
- ID number:
- 10621
Project Team
- Project lead
- danielle.lees@nice.org.uk
Email enquiries
If you have any queries please email Topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic prioritisation